Recombinant Human Albumin GTC has formed a joint venture with Fresenius to expand the commercial development opportunities of GTC's Recombinant Human Albumin (rhA) program. The joint venture will manage development of rhA for both the blood expander market and for the use of rhA in the excipient market. Research grade samples are now available for excipient and cell culture use.
Taurus is a joint venture of GTC Biotherapeutics and Fresenius-Kabi. This business venture is in place to develop, manufacture and market recombinant human albumin (rhA) for pharmaceutical excipient and selected cell culture applications.
For information regarding Taurus, please contact: transgenicsinfo@gtc-bio.com